MabVax Theraputics is focused on changing lives, by using our proven technology to develop novel therapies to provide significant benefits to people with cancer.

MabVax Therapeutics Holdings, Inc., is a clinical-stage biotechnology company focused on the development of a pipeline of human monoclonal antibody products that are based on the protective immune responses generated by patients who have been immunized against targeted cancers with our proprietary vaccines.

We study the protective immune response created by repeated vaccination of cancer patients. Our antibody discovery technology is able to identify and recover the antibodies patients have made against the vaccines and thus against the cancers. We search for the very best antibody any one patient makes against the vaccine and that one antibody can become our monoclonal antibody development candidate.

We have a novel therapeutic antibody product and a companion immunoPET diagnostic agent in Phase I clinical trials aimed at improving the diagnosis, management, and treatment of pancreatic cancer.

MabVax is planning to file an Investigational New Drug Application (IND) for MVT-1075, a HuMab-5B1 based radioimmunotherapy product, before the end of 2016. The company plans to initiate a Phase I trial in the first half of 2017. Key insights gained from the MVT-2163 program will be leveraged in this new trial. The radioimmunotherapy product is part of the company’s plan to develop additional potent analogs of the 5B1 antibody to treat especially difficult cancers.

We have a HuMab-5B1 based antibody drug conjugate product in preclinical development. We anticipate that we will file an IND at the end of 2017 and begin clinical trials in 2018.